ReviewEpidemiology and infection2008
Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005.
Review in Epidemiology and infection, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of Shigella species and antimicrobial resistance patterns in Africa: systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- Patterns of Bacillary Dysentery in China, 2005-2010.International journal of environmental research and public health · 2016Pooled it
- Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical and vaccine immunology : CVI · 2016Trial
- A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children.PLoS neglected tropical diseases · 2011Trial
- Genome-wide analysis exploring mechanisms used bymSystems · 2026Article
- Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.Nature reviews. Microbiology · 2025Review
- Safety, Tolerability, and Immunogenicity of the InvaplexVaccines · 2025Article
- Development of a Novel mRNA Vaccine AgainstBioinformatics and biology insights · 2025Article
- Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Multidrug-Resistant Shigella sonnei Bacteremia among Persons Experiencing Homelessness, Vancouver, British Columbia, Canada.Emerging infectious diseases · 2023Article
- Further characterization ofFrontiers in immunology · 2023Article
- The tale of the traveling cheese: Shigella in a lung transplant patient.Respiratory medicine case reports · 2022Article
- Relative transmissibility of shigellosis among different age groups: A modeling study in Hubei Province, China.PLoS neglected tropical diseases · 2021Article
- Laboratory-based surveillance of Shigella spp. from human clinical cases in Colombia, 1997-2018Biomedica : revista del Instituto Nacional de Salud · 2021Article
- Microbial levels on street foods and food preparation surfaces in Mangaung Metropolitan Municipality.Health SA = SA Gesondheid · 2021Article
- Influence of Shigella flexneri 2a O Antigen Acetylation on Its Bacteriophage Sf6 Receptor Activity and Bacterial Interaction with Human Cells.Journal of bacteriology · 2020Article
- An Oral Inoculation Infant Rabbit Model formBio · 2020Article
- A small RNA decreases the sensitivity of Shigella sonnei to norfloxacin.BMC research notes · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global incidence of Shigella infection has been estimated at 80-165 million episodes annually, with 99% of episodes occurring in the developing world. To identify contemporary gaps in the understanding of the global epidemiology of shigellosis, we conducted a review of the English-language scientific literature from 1984 to 2005, restricting the search to low and medium human development countries. Our review yielded 11 population-based studies of Shigella burden from seven countries. No population-based studies have been conducted in sub-Saharan Africa or in low human development countries. In studies done in all age groups, Shigella incidence varied from 0.6 to 107 episodes/1000 person-years. S. flexneri was the most commonly detected subgroup in the majority of studies. Case-fatality rates ranged from 0% to 2.6% in population-based studies and from 0% to 21% in facility-based studies. This review highlights the large gaps in data on the burden of Shigella infections for low human development index countries and, more specifically, for sub-Saharan Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.